After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Mereo Biopharma Group Plc ADR is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Mereo Biopharma Group Plc ADR is $583.33M. A total of 0.78 million shares were traded on the day, compared to an average of 757.85K shares.
In the most recent transaction, Scots-Knight Denise sold 60,046 shares of MREO for 4.22 per share on Sep 13 ’24. After the transaction, the Chief Executive Officer now owns 808,921 company shares. In a previous transaction on Sep 12 ’24, Scots-Knight Denise sold 28,611 shares at 4.47 per share. MREO shares that Chief Executive Officer owns now total 868,967.
Among the insiders who sold shares, Lewicki John A. disposed of 10,937 shares on Sep 13 ’24 at a per-share price of $4.22. This resulted in the Chief Scientific Officer holding 78,630 shares of MREO after the transaction. In another insider transaction, Lewicki John A. sold 5,212 shares at $4.47 per share on Sep 12 ’24. Company shares held by the Chief Scientific Officer now total 89,567.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, MREO has a high of $5.02 and a low of $1.95.
As of this writing, MREO has an earnings estimate of $0.01 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $0.08 per share and a lower estimate of -$0.02.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. MREO’s latest balance sheet shows that the firm has $127.27M in Cash & Short Term Investments as of fiscal 2021. There were $22.62M in debt and $16.93M in liabilities at the time. Its Book Value Per Share was $0.47, while its Total Shareholder’s Equity was $118.77M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MREO is Buy with a score of 5.00.
